6 University of California, Los Angeles, Los Angeles, CA, USA OBJECTIVES: In the treatment of benign prostatic hyperplasia (BPH), patient and physician concerns regarding vasodilatory side effects have led to the increased use of uroselective alphablockade as first-line therapy over less expensive, generic, nonuroselective agents. This study evaluated the relative economic impact of two currently available uroselective agents, alfuzosin and tamsulosin. METHODS: A 1-year decision analysis was undertaken to project the medical costs associated with treating symptomatic BPH patients with alfuzosin vs. tamsulosin. Key inputs included clinical data (efficacy and adverse events [AEs]), dosing, and routine medical care costs. Clinical data were derived from a comprehensive meta-analysis published as part of recently published BPH treatment guidelines, and resource utilization information was obtained from published sources and two nationwide physician surveys. RESULTS: Both agents had similar efficacy, however, safety profiles differed. Daily average acquisition costs, after adjusting for average wholesale price for tamsulosin ($1.99) and alfuzosin ($1.86) and increased daily average consumption (DACON) (17% of patients required a double dose of tamsulosin), were $1.98 vs. $1.58 per patient per day for tamsulosin and alfuzosin, respectively. This difference based upon price and DACON amounted to $146.00 per patient per year (PPPY) (tamsulosin = $722.70, alfuzosin = $576.70). Costs associated with tamsulosin-related AEs were estimated to be $4.59 PPPY, whereas, alfuzosin-related AEs were $2.25 PPPY ($2.34 PPPY difference). Therefore, in considering the price and DACON differential ($146.00) together with the differential in costs of treating AEs ($2.34), alfuzosin saved $148.34 PPPY, a 20% difference. CONCLUSIONS: Alfuzosin provides cost savings over tamsulosin in the treatment of patients with symptomatic BPH. Savings are realized primarily on the basis of total drug acquisition costs, followed by lower costs associated with treating side effects of therapy. Alfuzosin is a less expensive alternative to tamsulosin as a first-line clinically uroselective drug therapy in the management of men with BPH. This analysis addresses the cost-effectiveness of the extended release formulation of oxybutynin (Ditropan XL) relative to long-acting tolterodine (Detrol LA) for the treatment of overactive bladder in the US. METHODS: A previously validated state-transition model was used to compare the health economic outcomes over the course of one year using efficacy data from OPERA, a 3-month randomized, double-blind trial comparing Ditropan XL 10 mg once daily to Detrol LA 4 mg once daily, together with data from the literature to project outcomes beyond trial time. Five states were defined based on the severity of symptoms (number of incontinent episodes per week). Severity-specific costs (in 2003 US dollars) of pharmaceuticals, doctor visits, and pad or protection usage for incontinence in the US were used. RESULTS: Ditropan XL is expected to lead to superior outcomes and lower overall costs compared to Detrol LA. After one year, 4.6 more patients per 100 treated attain complete continence and an additional 2.4 more will have fewer than 7 incontinent episodes per week. Patients on Ditropan XL have almost 11 additional incontinence free days over the course of the year. Costs are expected to be an average of $43 lower per patient per year. Ditropan XL maintains its advantage over wide ranges of inputs, and outcomes are similar if analyses are limited to only 3 months, the duration of the OPERA trial. CONCLU-SIONS: These analyses suggest that Ditropan XL provides better health outcomes and lower costs compared to Detrol LA over a 1-year period.
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